^
    Back
    Association details:
    Biomarker:MYB-TYK2 fusion
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Zolinza (vorinostat) (HDAC inhibitor) +
    tanespimycin (BMS-722782) (HSP90 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Nature
    Title:

    Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia

    Published date:
    01/12/2022
    Excerpt:
    ...in vivo models of B-cell ALL from a patient harboring the MYB-TYK2 fusion gene...HDAC inhibitor, vorinostat and the HSP90 inhibitor, tanespimycin plus the JAK inhibitor, cerdulatinib as the most effective agents against cells expressing the MYB-TYK2 alteration.
    Secondary therapy:
    JAK inhibitor
    DOI:
    https://doi.org/10.1038/s41417-021-00421-6